摘要
目的 观察罗格列酮对老年胰岛素抵抗患者C反应蛋白 (CRP)和胰岛素敏感性的影响。方法 71例胰岛素抵抗患者分为罗格列酮治疗组 (4 6例 ,罗格列酮 ,4mg/d)和对照组 (2 5例 ,维生素C ,10 0mg/d) ,观察 2 4周 ,治疗前后检查空腹CRP、胰岛素、血脂和肝功能 ,测量血压、身高和体重。结果 (1)与基础值相比 ,罗格列酮组CRP、胰岛素抵抗指数 (COMA -IR)、收缩压、舒张压、胆固醇 (TC)、甘油三脂 (TG)、低密度脂蛋白胆固醇 (LDL -C)明显降低 (P <0 .0 5 ) ,高密度脂蛋白胆固醇 (HDL -C)轻度升高 ,有统计学差异 (P <0 .0 5 ) ,对照组以上各指标无明显变化 ;(2 )CRP与HOMA -IR、BMI、TC、TG、LDL -C、收缩压和舒张压呈正相关 ,与HDL -C呈负相关。结论 IR患者存在低度炎症状态 ,罗格列酮在改善IR及其相关代谢指标的同时 ,可降低CRP。
Objective To observe the effects of rosiglitazone on serum C-reaction protein and insulin sensitivity in the elderly with insulin resistance. Methods 71 aged patients with insulin resistance were diveided into rosiglitazone group (n=46, rosiglitazone 4mg daily) and control group (n=25, vitamin C 100mg daily), fasting serum CRP、Homa-IR、blood lipid and liver function were tested, blood pressure、 body height and body weight were recorded at basal and after 24 week observation.Results (1) Compared with basal value, CRP、Homa-IR、systolic pressure、diastolic pressure、TC、TG and LDL-C in rosiglitazone group decreased significantly (P<0.05), HDL-C increased slightly (P<0.05) after 24 weeks; (2) CRP had positive relationship with Homa-IR、BML、TC、TG、LDL-C、systolic pressure and diastolic pressure and negative relationship with HDL-C.Conclusion Patients with IR have low degree inflammation state, rosiglitazone can improve insulin resistance and related metabolic disturbance with CRP reduction.
出处
《中国临床保健杂志》
CAS
2005年第1期17-19,共3页
Chinese Journal of Clinical Healthcare